Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Receives Positive Coverage Decision for Veristrat

NEW YORK (GenomeWeb) – Biodesix said today that it has received a positive coverage decision from Horizon Blue Cross Blue Shield of New Jersey for its Veristrat test.

Horizon BCBS of New Jersey, which covers 3.8 million people in that state, determined as of May 10, 2016 that the test was a medically necessary benefit for patients with non-small cell lung cancer. With the decision, Veristrat is now covered for roughly 205 million people in the US, Biodesix said.

Veristrat, Biodesix's flagship product, is a blood-based proteomic test for assessing patient prognosis and predicting response to drug treatment in advanced NSCLC.